4,778 results match your criteria intravitreal bevacizumab


Incidence of Newly Registered Blindness From Age-Related Macular Degeneration in Australia Over a 21-Year Period: 1996-2016.

Asia Pac J Ophthalmol (Phila) 2021 Sep 16. Epub 2021 Sep 16.

Centre for Ophthalmology and Visual Science (Incorporating Lions Eye Institute), The University of Western Australia, Nedlands, Western Australia, Australia Department of Ophthalmology, Royal Perth Hospital, Perth, Western Australia, Australia School of Population and Global Health, The University of Western Australia, Crawley, Western Australia, Australia Department of Ophthalmology, Perth Children's Hospital, Nedlands, Western Australia, Australia.

Purpose: Report the age-standardized annual incidence of blindness registration due to age-related macular degeneration (AMD) in Australia in patients aged 50 years and older. Frequencies of photodynamic therapy (PDT) and intravitreal therapy (IVT) were examined.

Design: Retrospective observational study. Read More

View Article and Full-Text PDF
September 2021

Non-immediate drug hypersensitivity reactions secondary to intravitreal anti-vascular endothelial growth factors.

Graefes Arch Clin Exp Ophthalmol 2021 Sep 16. Epub 2021 Sep 16.

Department of Ophthalmology, Jules-Gonin Eye Hospital, University of Lausanne, Foundation Asile des Aveugles, Lausanne, Switzerland.

Purpose: To describe a series of non-immediate drug hypersensitivity reactions after intravitreal anti-vascular endothelial growth factors (anti-VEGFs).

Patients And Methods: Retrospective report of 6 patients with cutaneous non-immediate drug hypersensitivity reactions following intravitreal anti-VEGF injections, 4 after ranibizumab, 1 after bevacizumab and 1 after aflibercept.

Results: Clinical manifestations ranged from mild maculopapular rash, purpura to severe generalized erythroderma, with or without systemic involvement such as microscopic hematuria and proteinuria or fever. Read More

View Article and Full-Text PDF
September 2021

Evaluation of intraocular pressure change and anterior segment parameters after intravitreal bevacizumab injection - Cannula size matters.

Saudi J Ophthalmol 2020 Oct-Dec;34(4):247-250. Epub 2021 Jul 29.

Department of Ophthalmology, Uludağ University Hospital, Bursa, Turkey.

Purpose: To determine the changes in intraocular pressure (IOP) and anterior chamber parameters following intravitreal bevacizumab injection with different sizes of cannulas.

Methods: This clinical trial was conducted with 70 eyes of 70 patients who received an intravitreal injection of bevacizumab with 26 G (Group 1) or 30 G (Group 2) needle. Preinjection and postinjection 30-min IOP and pentacam measurements were obtained. Read More

View Article and Full-Text PDF

Strengthening retinopathy of prematurity screening and treatment services in Nigeria: a case study of activities, challenges and outcomes 2017-2020.

BMJ Open Ophthalmol 2021 23;6(1):e000645. Epub 2021 Aug 23.

Vitreoretinal Unit, Department of Ophthalmology, University of Benin Teaching Hospital, Benin City, Edo, Nigeria.

Objectives: Retinopathy of prematurity (ROP) will become a major cause of blindness in Nigerian children unless screening and treatment services expand. This article aims to describe the collaborative activities undertaken to improve services for ROP between 2017 and 2020 as well as the outcome of these activities in Nigeria.

Design: Descriptive case study. Read More

View Article and Full-Text PDF

Rare presentation of choroidal neovascularisation in a case of congenital hypertrophy of retinal pigment epithelium.

BMJ Case Rep 2021 Sep 12;14(9). Epub 2021 Sep 12.

Department of Ophthalmology, Abergele Hospital, Abergele, UK

A 22-year-old woman presented with a 2-week history of decreased vision, a central scotoma and metamorphopsia in her right eye. Her presenting visual acuity was 6/75 in the right eye and 6/6 in the left eye. Anterior segment examination was normal. Read More

View Article and Full-Text PDF
September 2021

Case Report: Postpartum Purtscher-like Retinopathy.

Optom Vis Sci 2021 Sep 9. Epub 2021 Sep 9.

St. Cloud VA Hospital, St. Cloud, Minnesota.

Significance: This case highlights various clinical features and resolution of Purtscher-like Retinopathy following childbirth.

Purpose: To present a case report of postpartum Purtscher-like Retinopathy and subsequent resolution following oral and intravitreal treatment.Case reportA 30-year-old woman presented with subjective visual disturbance and transient scotoma in her right eye seven days after giving birth. Read More

View Article and Full-Text PDF
September 2021

Impact of Anxiety Levels and Sleep Patterns on Perceived Pain During Intravitreal Bevacizumab Injections.

Ophthalmic Surg Lasers Imaging Retina 2021 Sep 1;52(9):498-504. Epub 2021 Sep 1.

Background And Objective: To evaluate the impact of anxiety and sleep patterns on intravitreal injection pain.

Patients And Methods: This prospective, noninterventional study surveyed patients scheduled for intravitreal injection by two retinal surgeons. A standard intravitreal injection technique was used. Read More

View Article and Full-Text PDF
September 2021

Subthreshold micropulse laser adjuvant to bevacizumab versus bevacizumab monotherapy in treating diabetic macular edema: one- year- follow-up.

Ther Adv Ophthalmol 2021 Jan-Dec;13:25158414211040887. Epub 2021 Sep 2.

Department B, Institut Hedi Rais d'ophtalmologie de Tunis, Tunis, Tunisia.

Purpose: To compare the therapeutic impact of combining intravitreal injections of bevacizumab (IVB) with micropulse laser (MPL) in central diffuse diabetic macular edema (DME) versus IVB monotherapy during 12 months follow-up.

Methods: We conducted a retrospective comparative study of 98 treatment-naive eyes (63 patients) with central diffuse DME. The first group of patients (IVB + MPL group,  = 49) was treated with 3 monthly IVB followed by MPL within 1 week after the third injection. Read More

View Article and Full-Text PDF
September 2021

Aflibercept clearance through the drainage system in a rat model.

Int J Retina Vitreous 2021 Sep 8;7(1):53. Epub 2021 Sep 8.

Department of Ophthalmology, Rabin Medical Center, Petach Tikva, Israel.

Background: As intravitreal anti-VEGF injections became the mainstay of treatment for many retinal diseases, the cause of a secondary sustained elevated intraocular pressure is still unclear. The aim of our study was to study the clearance of Aflibercept from the anterior chamber angle, in a rat model, to test if an aggregation exists.

Methods: Choroidal neovascular lesions (CNV) were induced in the right eye of 12 brown Norway rats, using indirect laser ophthalmoscope. Read More

View Article and Full-Text PDF
September 2021

Case Report: Subconjunctival Bevacizumab for the Treatment of Refractory Pseudophakic Cystoid Macular Edema.

Optom Vis Sci 2021 Aug;98(8):881-885

Department of Ophthalmology, Ondokuz Mayis University, Samsun, Turkey.

Significance: In this report, the authors present a case of a 63-year-old man with recurrent pseudophakic cystoid macular edema. Macular edema was refractory to the treatments with periocular corticosteroid injection and topical anti-inflammatory medications. It was treated with subconjunctival bevacizumab (2. Read More

View Article and Full-Text PDF

Long-term effects of intravitreal bevacizumab and aflibercept on intraocular pressure in wet age-related macular degeneration.

BMC Ophthalmol 2021 Aug 28;21(1):312. Epub 2021 Aug 28.

Department of Ophthalmology, Turku University Hospital, PO Box 52, 20521, Turku, Finland.

Background: To evaluate the incidence of sustained elevation of intraocular pressure (SE-IOP) associated with intravitreal injections of anti-vascular endothelial growth factors (anti-VEGF) bevacizumab and aflibercept in patients with wet age-related macular degeneration (wAMD).

Methods: A retrospective cohort study consisting of 120 eyes from 120 patients with anti-VEGF treatment for wAMD. Three different anti-VEGF groups were considered: i) 71 cases receiving bevacizumab only, ii) 49 cases receiving bevacizumab before switch to aflibercept, iii) 49 cases after switch to aflibercept. Read More

View Article and Full-Text PDF

Intravitreal Pharmacotherapies for Diabetic Macular Edema: A Report by the American Academy of Ophthalmology.

Ophthalmology 2021 Aug 23. Epub 2021 Aug 23.

Department of Ophthalmology, Vanderbilt University School of Medicine, Nashville, Tennessee.

Purpose: To review the evidence on the safety and efficacy of current anti-vascular endothelial growth factor (VEGF) and intravitreal corticosteroid pharmacotherapies for the treatment of diabetic macular edema (DME).

Methods: Literature searches were last conducted on May 13, 2020, in the PubMed database with no date restrictions and limited to articles published in English. The combined searches yielded 230 citations, of which 108 were reviewed in full text. Read More

View Article and Full-Text PDF

ASSOCIATIONS WITH RECURRENCE OF MACULAR EDEMA IN BRANCH RETINAL VEIN OCCLUSION AFTER THE DISCONTINUATION OF ANTI VASCULAR ENDOTHELIAL GROWTH FACTOR.

Retina 2021 Sep;41(9):1892-1900

Department of Ophthalmology, Catholic University of Daegu School of Medicine, Daegu, Korea; and.

Purpose: To identify factors predicting the recurrence of macular edema after the discontinuation of intravitreal antivascular endothelial growth factor injection in patients with branch retinal vein occlusion.

Methods: This retrospective study included only subjects who had discontinued injections at 3 months after the final bevacizumab injection due to fully resolved macular edema. Fifty-two eyes meeting the criteria were included in the study and divided into two groups (recurrence and no recurrence). Read More

View Article and Full-Text PDF
September 2021

Unilateral papilledema and peripapillary polypoidal choroidal vasculopathy as the presenting manifestations of intracranial hypertension.

Arq Bras Oftalmol 2021 Aug 18. Epub 2021 Aug 18.

Division of Ophthalmology, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil.

We have reported here the case of a 54-year-old woman with intracranial hypertension that presented with the unique features of unilateral papilledema and peripapillary polypoidal choroidal vasculopathy. Our investigations lead to the diagnosis of idiopathic intracranial hypertension and an incidental small right frontal meningioma. The patient was accordingly treated with oral acetazolamide, followed by three consecutive monthly intravitreal injections of bevacizumab, which resulted in the inactivation of the polypoidal choroidal vasculopathy, marked reduction of lipid exudation, and complete absorption of the subretinal fluid. Read More

View Article and Full-Text PDF

A case report: pseudoxanthoma elasticum diagnosed based on ocular angioid streaks and the curative effect of Conbercept treatment.

BMC Ophthalmol 2021 Aug 23;21(1):307. Epub 2021 Aug 23.

Department of Ophthalmology, Qingdao Municipal Hospital, Qingdao, Shandong, China.

Background: This article is a case report of pseudoxanthoma elasticum (PXE) which was diagnosed based on significant angioid streaks (AS) with choroidal neovascularization (CNV) and regain normal visual function by intravitreal injection with Conbercept.

Case Presentation: A 51-year-old woman was referred to the Ophthalmology Department of Qingdao Municipal Hospital (Qingdao, China) on September 14, 2020 for metamorphopsia and loss of vision in the left eye in the preceding three days. Past history: high myopia for more than 30 years, best corrected visual acuity (BCVA) of both eyes was 1. Read More

View Article and Full-Text PDF

Real-life management of neovascular age-related macular degeneration (nAMD) in France: a nationwide observational study using retrospective claims data.

J Med Econ 2021 Jan-Dec;24(1):1087-1097

Allergan, an AbbVie company, Courbevoie, France.

Aims: Intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy is standard care for neovascular age-related macular degeneration (nAMD), but the recommended monthly injection regimen is burdensome. Evidence suggests low injection/monitoring frequencies in clinical practice and suboptimal vision outcomes. This observational cohort study uses administrative claims data from the French national healthcare system to assess anti-VEGF treatment patterns and nAMD-specific healthcare resource demands and costs. Read More

View Article and Full-Text PDF

Economic evaluation of prevention of cystoid macular edema after cataract surgery in diabetic patients: ESCRS PREMED study report 6.

J Cataract Refract Surg 2021 Aug 18. Epub 2021 Aug 18.

University Eye Clinic Maastricht, Maastricht University Medical Center+, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands Department of Ophthalmology, Zuyderland Medical Center Heerlen, P.O. Box 5500, 6130 MB Sittard-Geleen, The Netherlands Department of Methodology and Statistics, Care and Public Health Research Institute (CAPHRI), Maastricht University Medical Center+, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands Department of Ophthalmology, Canisius Wilhelmina Hospital, P.O. Box 9015, 6500 GS Nijmegen, The Netherlands Department of Clinical Epidemiology and Medical Technology Assessment, Care and Public Health Research Institute (CAPHRI), Maastricht University Medical Center+, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands Department of Ophthalmology, Elisabeth-TweeSteden Hospital, P.O. Box 90151, 5000 LC Tilburg, The Netherlands Department of Ophthalmology, Antwerp University Hospital, Wilrijkstraat 10, 2650 Edegem, Belgium Department of Ophthalmology, Haaglanden Medical Center, P.O. Box 432, 2501 CK The Hague, The Netherlands Department of Ophthalmology, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands Eye Hospital Zonnestraal, 's-Gravenlandseweg 76, 1217 ET, Hilversum, The Netherlands.

Purpose: To investigate the cost-effectiveness of prophylactic treatments against cystoid macular edema (CME) after cataract surgery in diabetic patients.

Setting: Seven ophthalmology clinics in the Netherlands and Belgium.

Design: Prospective trial-based cost-effectiveness analysis using data from a European multicenter randomized clinical trial. Read More

View Article and Full-Text PDF

Self-sealing hyaluronic acid-coated 30-gauge intravitreal injection needles for preventing vitreous and drug reflux through needle passage.

Sci Rep 2021 Aug 20;11(1):16996. Epub 2021 Aug 20.

Department of Ophthalmology, Korea University College of Medicine, 148, Gurodong-ro, Guro-gu, Seoul, 08308, Republic of Korea.

Self-sealing hyaluronic acid (HA)-coated self-sealing 30-gauge needles exhibiting instant leakage prevention of intravitreal humor and injected drug were developed in this study. Ninety New Zealand rabbits were used in this study. We assessed dye regurgitation in intravitreal ICG dye injections using HA-coated needles (HA needle group) and conventional needles (control group). Read More

View Article and Full-Text PDF

Efficacy and Cost-Effectiveness of Anti-VEGF for Treating Diabetic Retinopathy in the Indian Population.

Clin Ophthalmol 2021 10;15:3341-3350. Epub 2021 Aug 10.

MGM Medical College, Kishanganj, Bihar, India.

Purpose: In the present study, we aimed to evaluate the efficacy, safety, and cost-effectiveness of the anti-vascular endothelial growth factor (anti-VEGF), namely ranibizumab (RBZ) or bevacizumab (BVZ), after either focal or grid or scatter laser photocoagulation, for the treatment of diabetic macular edema (DME) in the Indian population.

Methods: Retrospective data were collected in the Regional Institute of Ophthalmology, Kolkata, India between January 2018 and June 2019. Seventy-seven eyes received 3 consecutive monthly intravitreal injections of RBZ (0. Read More

View Article and Full-Text PDF

Comparison of Syringes With Intravitreal Anti-VEGF Drugs: Particle Burden and Protein Aggregates in Brolucizumab, Aflibercept and Bevacizumab.

Transl Vis Sci Technol 2021 Aug;10(9):21

Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics, Ludwig-Maximilians-University Munich, Germany.

Purpose: In a benchwork particle counting analytical evaluation, the number and type of particles in intravitreal injection formulations of three different agents against vascular endothelial growth factor were investigated.

Methods: Commercially available ready-to-use aflibercept and brolucizumab glass syringes, vials containing bevacizumab (off-label use in ophthalmology), and repackaged ready-to-use plastic syringes containing bevacizumab were tested without filtration. Total visible, subvisible, and nanoparticles numbers and size distributions were quantified using light obscuration, flow imaging, resonant mass measurement (RMM), tunable resistive pulse sensing, and dynamic light scattering. Read More

View Article and Full-Text PDF

Asymptomatic occlusive retinal vasculitis in newly diagnosed active tuberculosis.

Respir Med Case Rep 2021 24;33:101456. Epub 2021 Jun 24.

Port Macquarie Eye Centre, Port Macquarie, Australia.

Introduction: Worldwide, tuberculosis is the leading cause of death from an infectious disease. Ocular involvement can cause significant and permanent vision loss. Ocular manifestations of tuberculosis often present with visual symptoms. Read More

View Article and Full-Text PDF

Isolated juxtapapillary retinal capillary haemangioblastoma and exudative maculopathy in an elderly patient without von Hippel-Lindau syndrome: combined proton beam radiotherapy and intravitreal anti-VEGF.

BMJ Case Rep 2021 Aug 16;14(8). Epub 2021 Aug 16.

Manchester University NHS Foundation Trust, Manchester, UK

A 71-year-old Caucasian man presented with an isolated juxtapapillary retinal capillary haemangioblastoma on the superior and temporal left optic disc with active exudation resulting in macular intraretinal and subretinal fluid, reduced vision, scotoma and distortion with progression over 6 weeks. He did not have von Hippel-Lindau syndrome. After proton beam radiotherapy (PBR), the tumour size remained unchanged, but did not stop the exudation. Read More

View Article and Full-Text PDF

Description and management of retinopathy of prematurity reactivation after intravitreal antivascular endothelial growth factor therapy.

Curr Opin Ophthalmol 2021 Sep;32(5):468-474

Department of Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, University of Illinois at Chicago, Chicago, Illinois.

Purpose Of Review: To review the literature regarding reactivation of retinopathy of prematurity (ROP) after treatment with antivascular endothelial growth factor (anti-VEGF) agents.

Recent Findings: Reactivation can occur after anti-VEGF or laser. Risk factors for reactivation include patient and disease-related factors. Read More

View Article and Full-Text PDF
September 2021

Long-term outcomes of intravitreal anti-VEGF therapies in patients affected by neovascular age-related macular degeneration: a real-life study.

BMC Ophthalmol 2021 Aug 14;21(1):300. Epub 2021 Aug 14.

Western Eye Hospital, Imperial College Healthcare NHS Trust, 171 Marylebone Rd, London, NW1 5QH, UK.

Purpose: To describe real-life data from wet age-related macular degeneration (AMD) patients treated with anti-vascular endothelial growth factors (VEGFs) and to compare our results with previous studies and clinical trials.

Methods: This retrospective monocentric cohort study analyzed 865 eyes of 780 wet-AMD patients treated with an anti-VEGF treat-and-extend regimen over a long-term follow-up period. Aflibercept and Ranibizumab were considered first-line agents whereas Bevacizumab was reserved for use on a compassionate basis in patients not meeting treatment criteria. Read More

View Article and Full-Text PDF

Intraocular pressure decreases in eyes with glaucoma-related diagnoses after conversion to aflibercept for treatment-resistant age-related macular degeneration.

Eye (Lond) 2021 Aug 12. Epub 2021 Aug 12.

Department of Ophthalmology, Lahey Hospital & Medical Center, Peabody, MA, USA.

Objective: To understand intraocular pressure (IOP) response after switching from intravitreal bevacizumab (IVB) and/or ranibizumab (IVR) to intravitreal aflibercept (IVA) for treatment-resistant neovascular age-related macular degeneration (nAMD) in patients with and without coexisting glaucoma-related diagnoses.

Methods: Retrospective, cross-sectional comparative case series of 62 eyes of 58 patients treated with intravitreal injection for nAMD from March 2010 to April 2018. Patients with glaucoma-related diagnoses, defined here as open-angle glaucoma or suspicion of open-angle glaucoma, ocular hypertension, and/or narrow-angle glaucoma, were compared to those without glaucoma. Read More

View Article and Full-Text PDF

Optical coherence tomography angiography and multimodal imaging in the management of coats' disease.

Am J Ophthalmol Case Rep 2021 Sep 24;23:101177. Epub 2021 Jul 24.

Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA.

Purpose: To illustrate the spectrum of clinical and imaging features in patients with unilateral Coats' disease at baseline and in response to treatment with laser, intravitreal bevacizumab, and regional steroids.

Observations: Telangiectasias, macular exudates, and vascular leakage were present in all 3 patients included in this series. After treatment with laser and bevacizumab, OCT angiography findings included an anomalous foveal vascular loop and chorioretinal anastomoses. Read More

View Article and Full-Text PDF
September 2021

Treatment of Sorsby fundus dystrophy with anti-tumor necrosis factor-alpha medication.

Authors:
Richard F Spaide

Eye (Lond) 2021 Aug 10. Epub 2021 Aug 10.

Vitreous Retina Macula Consultants of New York, New York, NY, USA.

Purpose: Tissue inhibitor of matrix metalloproteinase (TIMP)-3 has many functions, including preventing the constituent formation of tumor necrosis factor-alpha (TNFα) in tissue. Sorsby macular dystrophy is caused by a mutation in the gene responsible for TIMP-3, suggesting a potential treatment.

Methods: Comprehensive ophthalmologic examination with multimodal imaging to include optical coherence tomography (OCT) and OCT angiography were used to evaluate a patient with Sorsby fundus dystrophy treated first with intravitreal triamcinolone, then with adalimumab. Read More

View Article and Full-Text PDF

Molecular Features of Classic Retinal Drugs, Retinal Therapeutic Targets and Emerging Treatments.

Pharmaceutics 2021 Jul 20;13(7). Epub 2021 Jul 20.

IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Via Olgettina 60, 20132 Milan, Italy.

The management of exudative retinal diseases underwent a revolution due to the introduction of intravitreal treatments. There are two main classes of intravitreal drugs, namely anti-vascular endothelial growth factors (anti-VEGF) and corticosteroids molecules. The clinical course and the outcome of retinal diseases radically changed thanks to the efficacy of these molecules in determining the regression of the exudation and the restoration of the macular profile. Read More

View Article and Full-Text PDF

Five-year outcomes of eyes initially enrolled in the 2-year BEVORDEX trial of bevacizumab or dexamethasone implants for diabetic macular oedema.

Br J Ophthalmol 2021 Aug 2. Epub 2021 Aug 2.

Department of Ophthalmology, The University of Sydney Save Sight Institute, Sydney, New South Wales, Australia.

Background: The BEVORDEX trial compared outcomes of eyes with diabetic macular oedema (DMO) randomised to receive either intravitreal dexamethasone (DEX-) implant or bevacizumab over 2 years. We assessed long-term efficacy and safety outcomes 5 years from enrolment.

Methods: Patients received standard clinical care after they finished the study. Read More

View Article and Full-Text PDF